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Summary. Macrophages activated in a variety of ways in vivo 
as well as in vitro release a cytotoxic factor upon LPS stimula- 
tion. Physicochemical characterization revealed a heat-stable 
60,000 D protein with an isoelectric point at pH 4.8. This cyto- 
toxin is one of the efl%ctor molecules in tumor cell killing by 
activated macrophages since cytolysis can be inhibited by anti- 
bodies directed against he cytotoxic factor. 
Key words: Cytotoxic Factor Lymphokines - Host Resistance 
- Tumor-cytotoxicity - Lipopotysaccharides 
Introduction 
The endotoxic principle of lipopolysaccharides (LPS) from gram- 
negative bacteria seems to reside in its Lipid A component [1]. 
The administration of LPS or Lipid A into a susceptible host 
provokes a range of biological effects. Some of these effects 
can be attributed to direct actions of LPS on targets in the 
host organism. The majority of host responses, however, is me- 
diated by soluble factors elicited upon the LPS stimulus. The 
production of interferon, colony stimulating factor and lympho- 
cyte activating factor - to mention just a few activities - can 
be demonstrated after LPS application to the appropriate host 
[2-4]. Such mediators have been subject of intensive modern 
research and they have been shown to modulate immune reac- 
tions by acting on the immune system in sometimes complex 
ways (for review see [5, 6]). 
Characterization of Endotoxin-Induced Cytotoxic Factor 
We studied the induction and properties of one mediator with 
a rather direct way of action. After administration of LPS to 
Mycobacterium boris BCG-infected mice, the sera of these ani- 
mals show cytotoxic activity for tumor cells in vivo (tumor necro- 
sis factor) as well as in vitro [7, 8]. This cytotoxic activity is 
measured in vitro by label release of [3H]thymidine-prelabeled 
target cells after 48 h of incubation. Maximal titers of cytotoxic 
activity were detected 2 hat ter  LPS treatment of mice which 
were infected with BCG 14 days before. Physicochemical charac- 
terization of the cytotoxic activity revealed a heat-stable (56 ° C, 
30 min) entity with a molecular weight of about 60,000. The 
isoelectric point was at pH 4.8 measured by flat bed isoelectric 
focusing. The activity of the cytotoxin was lost after treatment 
with protease, trypsin and chymotrypsin, but was not altered 
by the serine esterase inhibitor diisopropyl fluorophosphate. 
Physcicochemical characteristics reported for the tumor necrosis 
factor were very similar. However, the isolated 60,000 D cyto- 
toxin failed to induce tumor necrosis in vivo [9] and, therefore, 
cannot by itself be responsible for the necrotic effect after LPS 
administration. 
Cytotoxic Factor as Effector Molecule 
for Macrophage Cytotoxieity 
Release of cytotoxic factor was shown to be T-cell independent 
but dependent on Lipid A sensitivity. Serum of BCG-infected, 
T-cell deficient ude mice developed strong cytotoxic activity after 
LPS treatment, whereas no cytotoxicity could be measured in 
lipid A resistent C3H/HeJ mice. In in vitro experiments, macro- 
phages were identified as cellular sources of this cytotoxin. Mac- 
Table 1. Correlation between macrophage tumoricidal activity and re- 
lease of cytotoxic factor 
Macrophages Macrophage Release of cytotoxic 
from mice tumoricidal factor b 
treated with activity ~ 
- LPS + LPS 
BCG 2,240±130(26) 470+20(11) 1,410+ 60(33) 
Pyran 2,380±250 (27) 640_+ 10 (15) 1,600_+ 110 (38) 
C. parvum 2,020_+ 130 (23) 560_+20 (13) 1,640+_ 80 (39) 
PBS 770_+ 70 (9) 340+_30 (8) 480+_ 60(11) 
Starch 620_+ 20 (7) 360_+80 (8) 360+_60 (8) 
Latex 790-+ 10 (9) 340-+40 (8) 400_+ 60 (9) 
No macrophages 680± 70 (8) 220+_ 70 (5) 
SDS total counts 8,740 ± 700 (100) 4,250 +- 170 (100) 
" Adherent peritoneal exudate cells from mice treated i.p. with 2 × 10 a 
viable BCG, 500 gg of pyran, 1.4 mg of C, parvum, 2% starch in 
water, or latex beads 7 days previously or with PBS 1 clay previously 
were incubated with [3H]TdR-prelabeled tumor cells. Cytotoxicity 
(released [3H]TdR) was estimated at 48 h and expressed as mean 
counts per minute ± SEM for duplicate cultures and as percentage 
of SDS tota! counts (in parentheses) 
b For release of cytotoxic factor, the cytotoxic activity of 2-h superna- 
tants from 10 ~ adherent peritoneal exudate cells with or without 
10 gg E. col± K 235 LPS was tested on [aH]TdR-prelabeled L929 
cells. Cytotoxicity (released [3H]TdR) was estimated at 48 h and 
expressed as mean counts per minute + SEM for duplicate cultures 
and as percentage of SDS total counts (in parentheses) 
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Table 2. Inhibition of macrophage cytotoxicity by IgG against serum- 
derived cytotoxic factor 
Mouse strain Stimulus Cytotoxicity a 
IgG u Medium 
C3H/HeN BCG 480 + 50 (40) 1~060_+ 40 (89) 
Pyran 560± 30 (47) 1,030± 90 (86) 
C. parvum 770 + 30 (64) 1,070_+ 80 (90) 
C57BL/6N BCG 470 ± 40 (40) 780 ± 100 (65) 
Spontaneous release 170_+ 10 (14) 
SDS total counts 1,200 + 90 (100) 
a Adherent peritoneaI exudate cells from mice treated i.p. with 2"× 106 
viable BCG, 500 tag of pyran, or 1.4 mg of C. parvum 7 days pre- 
viously were incubated with [3H]TdR-labeled tumor cells at a 10:1 
effector: target ratio. Cytotoxicity was estimated by [3H]TdR release 
at 48 h and expressed as mean counts per minute __+ SEM for dupli- 
cate cultures and as percentage of SDS total counts (in parentheses) 
b Purified IgG against cytotoxic factor at a final concentration of 
0.5 mg/ml was added to the cultures 
rophage enriched peritoneal exudate cells from BCG infected 
animals as well as macrophage-like tumor cells (PU 5-1.8) and 
peritoneal macrophages propagated in vitro with macrophage 
growth factor were able to release the cytotoxic factor upon 
LPS stimulus [10]. 
Activation of the macrophages and minute amounts of LPS 
as trigger were absolute requirements for factor release as shown 
in Table 1. Besides the in vivo activation with BCG, Pyran or 
C. parvum, treatment in vitro with tymphokines containing mac- 
rophage activating factor also resulted in cytotoxic macrophages 
that were susceptible for induction of cytotoxic factor release 
by LPS. TumoricidaI activity of the macrophages correlated well 
with the ability" to release soluble cytotoxin independent on the 
method of activation. 
A rabbit antiserum against partially purified serum cytotoxic 
factor inhibited the cytotoxic activity of serum-derived as well 
as in vitro elicited factor [11]. When purified IgG directed against 
the cytotoxin was added to cultures of cytotoxic macrophages 
and tumor cells, macrophage cytotoxicity was markedly reduced 
(Table 2). Again. not only the cytotoxicity of in vivo activated 
macrophages but also of lymphokine activated macrophages was 
inhibited. The inhibitory effect of the antibodies was not due 
to damage of the cytotoxic effector cell since other macrophage 
functions like antibody-mediated cytotoxicity or chemotaxis were 
not affected and activated macrophages remained cytotoxic after 
removal of the antibody. 
It seems to be clear from these studies that this cytotoxic 
factor is at least one of the effector molecules in tumor cell 
killing by activated macrophages. Also, sufficiently activated 
macrophages are well known to be antimicrobial [12]. The same 
serum that contains the tumoricidal activity was also shown 
to enhance resistance to bacterial infections [13]. Of course, the 
cytotoxic serum described here also displays a multitude of other 
LPS induced activities and it remains to be investigated if the 




From these and many other studies it becomes obvious that 
administration of LPS or lipid A to an infected animal has 
tremendous effects. Current evidence is consistent with the hy- 
pothesis that during infection macrophages become activated 
by lymphokines that are secreted by specifically sensitized T 
lymphocytes. This can be mimiked by activating macrophages 
for tumoricidal activity with lymphokines in vitro. These acti- 
vated macrophages seem to be exquisitly sensitive to LPS-action 
judged by the extremly small amounts necessary as stimulus. 
We have shown in our studies that LPS acts like a trigger 
on the activated macrophage and it induces a burst of cytotoxic 
activity within less than 2 h. It needs to be clarified in the future 
if protection in one or the other model system can be ascribed 
to just one of the LPS induced mediators or if protection is 
rather the result of concerted action of various factors with 
the immune cells. Three different pathways of LPS action in 
the sensitized animal can be shown: 1) the direct effect of Lipid 
A on cells, 2) executive functions of LPS-induced mediators 
and 3) intercellular communication and modulation of the im- 
mune system via LPS-elicited lymphokines. 
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